- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02100722
A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease (FAME 3)
Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Trial A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The FAME 3 trial is a multicenter, international, randomized, controlled noninferiority trial. All patients with multivessel CAD (not involving the left main) will be screened by the site's Heart Team (including but not limited to an interventional cardiologist, cardiac surgeon and research coordinator). If all agree that the patient can be treated either with FFR-guided PCI or CABG, and all inclusion criteria are met and no exclusion criteria are met, then the patient will be randomized.
Baseline clinical, functional, laboratory and electrocardiographic data will be obtained. Patients will receive treatment within 4 weeks of randomization. Patients randomized to CABG will receive state of the art therapy at the discretion of the local surgeon with a strong emphasis on arterial revascularization. Patients undergoing PCI will have FFR measured with a St. Jude Medical coronary pressure wire across all lesions. If the FFR is ≤0.80, then PCI will be performed with the Medtronic Resolute Integrity drug-eluting stent (DES) as per usual routine. If the FFR is >0.80 then PCI will be deferred.
All patients will receive medical therapy as per published guidelines. Patients will follow-up at 1 and 6 months, and 1 and 3 years with an evaluation of clinical status, functional status, medications and events. Follow-up may be extended to 5 years, if funding allows.
Core lab analyses will include formal quantitative coronary angiography (QCA) of the baseline angiograms with calculation of the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score and Functional SYNTAX Score.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Frankston, Australia
- Peninsula Health
-
Melbourne, Australia
- St. Vincent's Hospital Melbourne
-
Sydney, Australia
- Concord Hospital
-
Sydney, Australia
- Royal North Shore
-
Sydney, Australia
- University of Sydney
-
-
-
-
-
Aalst, Belgium, 9300 Aalst
- Cardiovascular Center Aalst
-
-
-
-
-
Montreal, Canada
- Le'Centre Hospitalier de l'Universite de Montreal
-
Ontario, Canada
- York PCI Group Inc
-
Ottawa, Canada
- University of Ottawa Heart Institute
-
-
-
-
-
Brno, Czechia
- Masaryk University and University Hospital Brno
-
-
-
-
-
Copenhagen, Denmark
- Rigshospitalet University Hospital
-
-
-
-
-
Lyon, France
- Cardiovascular Hospital
-
-
-
-
-
Budapest, Hungary
- Hungarian Institute of Cardiology
-
-
-
-
-
Seoul, Korea, Republic of
- Asan Medical Center
-
-
-
-
-
Vilnius, Lithuania
- Vilnius University Hospital Santariskiu Klinikos
-
-
-
-
-
Eindhoven, Netherlands, 5623 EJ
- Catharina Hospital Eindhoven
-
The Hague, Netherlands
- HagaZiekenhuis
-
Zwolle, Netherlands
- Isala Klinieken
-
-
-
-
-
Hamilton, New Zealand
- Waikato Hospital
-
-
-
-
-
Stavanger, Norway
- Stavanger University Hospital
-
-
-
-
-
Belgrade, Serbia
- University Clinical Center of Serbia
-
Kragujevac, Serbia
- Clinical Center Kragujevac
-
-
-
-
-
Goteborg, Sweden
- Sahlgrenska University Hospital
-
Stockholm, Sweden
- Danderyds sjukhus
-
Stockholm, Sweden
- Karolinska Institutet, Dep of clinical science and education, Södersjukhuset
-
-
-
-
-
Cardiff, United Kingdom
- Wales Heart Research Institute
-
Coventry And Warwickshire, United Kingdom
- University Hospitals Coventry and Warwickshire
-
Glasgow, United Kingdom
- Golden Jubilee National Hospital
-
London, United Kingdom
- Kings College Hospital
-
London, United Kingdom
- St. Thomas' Hospital
-
Manchester, United Kingdom
- Wythenshawe Hospital
-
Oxford, United Kingdom
- Oxford University Hospital NHS Trust
-
Southhampton, United Kingdom
- Southampton University Hospitals NHS Trust
-
-
-
-
California
-
Palo Alto, California, United States
- Palo Alto VA
-
Stanford, California, United States, 94305-2004
- Stanford University
-
-
Georgia
-
Decatur, Georgia, United States
- Atlanta VA Medical Center
-
-
Illinois
-
Chicago, Illinois, United States
- Jesse Brown VA Medical Center
-
-
Kansas
-
Lawrence, Kansas, United States
- University of Kansas Medical Center
-
-
Kentucky
-
Lexington, Kentucky, United States
- Lexinton VA
-
Lexington, Kentucky, United States
- University of Kentucky Medical Center
-
-
Massachusetts
-
Springfield, Massachusetts, United States
- Baystate Medical Center
-
-
Minnesota
-
Saint Paul, Minnesota, United States
- HealthEast St. Joseph's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
- Penn Presbyterian Medical Center
-
-
Tennessee
-
Nashville, Tennessee, United States
- Centennial Heart
-
-
Texas
-
Houston, Texas, United States
- Houston Methodist Hospital
-
-
Virginia
-
Charlottesville, Virginia, United States
- University of Virginia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 1. Age ≥ 21 years with angina and/or evidence of myocardial ischemia
- 2. Three vessel CAD, defined as ≥ 50% diameter stenosis by visual estimation in each of the three major epicardial vessels or major side branches, but not involving left main coronary artery, and amenable to revascularization by both PCI and CABG as determined by the Heart Team. Patients with a non-dominant right coronary artery may be included if only the left anterior descending artery (LAD) and left circumflex have ≥50% stenosis
- 3. Willing and able to provide informed, written consent
Exclusion Criteria:
- 1. Requirement for other cardiac or non-cardiac surgical procedure (e.g., valve replacement, carotid revascularization)
- 2. Cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support
- 3. Recent STEMI (<5 days prior to randomization)
- 4. Ongoing Non STEMI with biomarkers (cardiac troponin) still rising
- 5. Known left ventricular ejection fraction <30%
- 6. Life expectancy < 2 years
- 7. Requiring renal replacement therapy
- 8. Undergoing evaluation for organ transplantation
- 9. Participation or planned participation in another clinical trial, except for observational registries
- 10. Pregnancy
- 11. Inability to take dual antiplatelet therapy for six months
- 12. Previous CABG
- 13. Left main disease requiring revascularization
- 14. Extremely calcified or tortuous vessels precluding FFR measurement
- 15. Any target lesion with in-stent drug-eluting stent restenosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: FFR guided PCI
Patients undergoing PCI will have FFR measured with a St. Jude Medical coronary pressure wire across all lesions.
If the FFR is ≤0.80, then PCI will be performed with the Medtronic Resolute Integrity (or Onyx) drug-eluting stent (DES) as per usual routine.
If the FFR is >0.80 then PCI will be deferred.
Only those sites with prior experience measuring FFR will be included in the FAME 3 trial.
These patients in whom FFR of a particular lesion was not possible will be included in all analyses based on the intention to treat principle.
|
Other Names:
Durable polymer zotarolimus-eluting stent
Durable polymer zotarolimus-eluting stent
|
Active Comparator: CABG
CABG will be performed as per clinical routine at each participating center.
Both off-pump and on-pump surgery are acceptable, as long as the surgeon and the site are experienced in the particular technique.
An internal mammary graft to the LAD should be attempted in all cases, if feasible.
Complete arterial revascularization is strongly recommended, however, each center should use a conduit strategy with which they are most comfortable.
All vessels ≥ 1,5 mm in diameter and with ≥ 50% stenosis should be bypassed, if technically feasible.
|
Coronary Artery Bypass Graft Surgery (CABG)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MACCE
Time Frame: 1 year
|
Death, MI, stroke and any repeat revascularization (MACCE) will be evaluated at 1 year, where subjects contribute data from time of randomization until the occurrence of MACCE or one year follow-up, whichever occurs first.
Subjects who die or are lost to follow up before 1 year will be censored at their last recorded activity.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Experiencing Death, MI, or Stroke
Time Frame: 1 year
|
Subjects who died or are lost to follow up before this time were censored at their last recorded activity.
|
1 year
|
Death
Time Frame: 1 year
|
Death evaluated excluding patients lost to follow-up from each arm
|
1 year
|
Number of Participants Experiencing Myocardial Infarction
Time Frame: 1 year
|
MI evaluated excluding patients lost to follow-up from each arm
|
1 year
|
Number of Participants Experiencing Stroke
Time Frame: 1 year
|
Stroke evaluated excluding patients lost to follow-up from each arm.
|
1 year
|
Number of Participants Requiring Repeat Revascularization
Time Frame: 1 year
|
Any repeat revascularization evaluated excluding patients lost to follow-up from each arm
|
1 year
|
Number of Participants Experiencing BARC Type 3-5 Bleeding
Time Frame: 1 year
|
Bleeding Academic Research Consortium (BARC) type 3-5 indicates severe bleeding.
|
1 year
|
Number of Participants Experiencing Acute Kidney Injury
Time Frame: 1 year
|
1 year
|
|
Number of Participants Experiencing Atrial Fibrillation or Clinically Significant Arrhythmia
Time Frame: 1 year
|
1 year
|
|
Number of Participants Experiencing Definite Stent Thrombosis
Time Frame: 1 year
|
1 year
|
|
Number of Participants Experiencing Definite Symptomatic Graft Occlusion
Time Frame: 1 year
|
1 year
|
|
Number of Participants Requiring Rehospitalization Within 30 Days
Time Frame: 30 days
|
30 days
|
|
MACCE
Time Frame: 2 years, 3 years, 5 years
|
Death, MI, stroke and any repeat revascularization (MACCE) rate at 2 years, 3 years and 5 years
|
2 years, 3 years, 5 years
|
Key Secondary Outcome: Composite of Death From Any Cause, Myocardial Infarction, or Stroke
Time Frame: 3 years
|
Death, MI, or stroke at 3-year follow-up
|
3 years
|
Death, MI, or Stroke at 5 Years
Time Frame: 5 years
|
Death, MI, or stroke at 5 years
|
5 years
|
Individual Components of Primary Outcome
Time Frame: 3 years, 5 years
|
Individual components of primary outcome
|
3 years, 5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: William F Fearon, MD, Stanford University
- Principal Investigator: Nico HJ Pijls, MD, PhD, Catharina Hospital Eindhoven, The Netherlands
- Principal Investigator: Bernard De Bruyne, MD, PhD, VZW Cardiovascular Research Center Aalst
Publications and helpful links
General Publications
- Zimmermann FM, De Bruyne B, Pijls NH, Desai M, Oldroyd KG, Park SJ, Reardon MJ, Wendler O, Woo J, Yeung AC, Fearon WF. Rationale and design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: a comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary artery disease. Am Heart J. 2015 Oct;170(4):619-626.e2. doi: 10.1016/j.ahj.2015.06.024. Epub 2015 Jul 9.
- Zimmermann FM, De Bruyne B, Pijls NHJ, Desai M, Oldroyd KG, Reardon MJ, Wendler O, Woo J, Yeung AC, Fearon WF. A protocol update of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 trial: A comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary artery disease. Am Heart J. 2019 Aug;214:156-157. doi: 10.1016/j.ahj.2019.04.012. Epub 2019 Apr 29. No abstract available.
- Fearon WF, Zimmermann FM, De Bruyne B, Piroth Z, van Straten AHM, Szekely L, Davidavicius G, Kalinauskas G, Mansour S, Kharbanda R, Ostlund-Papadogeorgos N, Aminian A, Oldroyd KG, Al-Attar N, Jagic N, Dambrink JE, Kala P, Angeras O, MacCarthy P, Wendler O, Casselman F, Witt N, Mavromatis K, Miner SES, Sarma J, Engstrom T, Christiansen EH, Tonino PAL, Reardon MJ, Lu D, Ding VY, Kobayashi Y, Hlatky MA, Mahaffey KW, Desai M, Woo YJ, Yeung AC, Pijls NHJ; FAME 3 Investigators. Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery. N Engl J Med. 2022 Jan 13;386(2):128-137. doi: 10.1056/NEJMoa2112299. Epub 2021 Nov 4.
- Piroth Z, Otsuki H, Zimmermann FM, Ferenci T, Keulards DCJ, Yeung AC, Pijls NHJ, De Bruyne B, Fearon WF. Prognostic Value of Measuring Fractional Flow Reserve After Percutaneous Coronary Intervention in Patients With Complex Coronary Artery Disease: Insights From the FAME 3 Trial. Circ Cardiovasc Interv. 2022 Nov;15(11):884-891. doi: 10.1161/CIRCINTERVENTIONS.122.012542. Epub 2022 Sep 19.
- Fearon WF, Zimmermann FM, Ding VY, Zelis JM, Piroth Z, Davidavicius G, Mansour S, Kharbanda R, Ostlund-Papadogeorgos N, Oldroyd KG, Wendler O, Reardon MJ, Woo YJ, Yeung AC, Pijls NHJ, De Bruyne B, Desai M, Hlatky MA; FAME 3 Investigators. Quality of Life After Fractional Flow Reserve-Guided PCI Compared With Coronary Bypass Surgery. Circulation. 2022 May 31;145(22):1655-1662. doi: 10.1161/CIRCULATIONAHA.122.060049. Epub 2022 Apr 2.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FAME 3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Disease
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking University Third HospitalCompletedCoronary Microvascular Dysfunction | Obstructive Coronary Heart DiseaseChina
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of
-
Istanbul UniversityCompletedIschemic Heart Disease | Coronary Microvascular Disease | Microvascular Angina | Coronary Microvascular Dysfunction | Non-Obstructive Coronary Atherosclerosis | Microvascular Coronary Artery DiseaseTurkey
-
Centro de estudios en Cardiologia IntervencionistaCompletedCoronary Heart Disease | Coronary RestenosisArgentina
-
Deutsches Herzzentrum MuenchenCompletedCoronary Heart DiseaseGermany
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
National Heart Centre SingaporeUnknownCoronary Heart DiseaseSingapore
Clinical Trials on FFR guided PCI
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaNot yet recruitingCoronary Artery Disease | Coronary Artery Disease Left MainKorea, Republic of
-
Catholic University of the Sacred HeartUnknownIschemic Heart DiseaseItaly
-
University of LimerickUnknownSTEMI | Multivessel Coronary Artery Disease | FFR Guided PCIIreland
-
Vilnius University Hospital Santaros KlinikosVilnius UniversityCompleted
-
University Hospital of FerraraActive, not recruitingCoronary Artery Disease | Percutaneous Coronary InterventionItaly
-
University Hospital of FerraraRecruitingMyocardial InfarctionItaly, Pakistan
-
Vilnius University Hospital Santaros KlinikosVilnius UniversityCompletedMyocardial Infarction | Myocardial Ischemia | Coronary Artery Disease
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, France; AbbottActive, not recruitingAcute Myocardial Infarction | Acute ST Segment Elevation Myocardial Infarction | Multi Vessel Coronary Artery DiseaseFrance
-
Maatschap Cardiologie ZwolleMedtronicActive, not recruitingCABG | Aortic Stenosis | Fractional Flow Reserve | PCI | Multi Vessel Coronary Artery Disease | TAVINetherlands, France, Spain, Denmark, Austria, Poland, Portugal, Greece, Germany, Slovakia
-
University of JenaKKS NetzwerkTerminatedCoronary Artery DiseaseGermany